Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company now aims for single-digit growth and about a 10% total return, focusing on predictability rather than rapid expansion. The business is viewed as low risk due to recurring revenue, minimal acquisition disruption, and sector resilience.
ISS A/S is actively executing its share buyback programme announced in February 2026, aiming to redistribute excess cash to shareholders by reducing share capital and fulfilling share-based incentive obligations. The company has repurchased shares wo...
Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed its share transactions on October 9, 2026. The bank purchased 150,000 ordinary shares at prices between 1092.5 and 1094, while selling 167,967 shares at prices between 1...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed transactions involving the purchase and sale of 74,820 ordinary shares on October 9, 2026. The shares were traded at prices between 307.5 and 308.5 per unit. There were no derivative ...
Investec Bank plc, acting as advisor and broker to Gooch & Housego plc, disclosed the sale of 2,386 ordinary shares at a price of 1,230 per share on October 9, 2026. There were no derivative transactions or other dealing arrangements reported. This t...
FLSmidth & Co. A/S continued its share buy-back program initiated in May 2026, repurchasing 48,000 shares between October 5 and 8, 2026, at an average price ranging from DKK 548.31 to DKK 572.56 per share. The total value of shares bought back in thi...
